{"id":34,"date":"2020-10-20T01:37:20","date_gmt":"2020-10-20T01:37:20","guid":{"rendered":"https:\/\/tz.investorportal.com.au\/?page_id=34"},"modified":"2025-06-20T13:02:38","modified_gmt":"2025-06-20T03:02:38","slug":"news-media","status":"publish","type":"page","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/","title":{"rendered":"News &#038; media"},"content":{"rendered":"\n<section id=\"article \" class=\"wp-block-gutentor-m3 section-gm9bf6b1e gutentor-module gutentor-container-cover has-color-bg has-custom-bg article-new\"><div class=\"grid-container\">\n<section id=\"gmfb025f2\" class=\"wp-block-gutentor-m4 section-gmfb025f2 gutentor-module gutentor-advanced-columns pb0\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gme0c25d\" class=\"wp-block-gutentor-m4-col col-gme0c25d gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gme0c25d\" class=\"section-gme0c25d gutentor-col-wrap\">\n<h2 class=\"wp-block-heading has-text-align-left fz36 fz30 has-text-color\" style=\"color:#0089c4;font-size:32px\">Media<\/h2>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gmc5d8cfd\" class=\"wp-block-gutentor-m4 section-gmc5d8cfd gutentor-module gutentor-advanced-columns pd0 search\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm965311\" class=\"wp-block-gutentor-m4-col col-gm965311 gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gm965311\" class=\"section-gm965311 gutentor-col-wrap\">\n<form role=\"search\" method=\"get\" class=\"search-form search-tag\" action=\"https:\/\/template.reachmarkets.com.au\/investorportal\/\">\n<img decoding=\"async\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2021\/09\/search.svg\" class=\"search_icon_image\">\n<input type=\"search\" class=\"search-field\" placeholder=\"Search for media\" value=\"\" name=\"s\"><input type=\"hidden\" name=\"post_type\" value=\"post\"><\/form>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<h4 class=\"wp-block-heading\" style=\"font-size:18px\">Media type<\/h4>\n\n\n<div class=\"project-container\">                    <ul class=\"filter txt-center margin\" data-md=\"0\" data-json='{\"add_class\":\"size-light\",\"perpage\":\"9\",\"order\":\"DESC\",\"orderby\":\"\",\"cat_id\":\"\",\"show_pagination\":\"1\",\"cat_notid\":\"\",\"show_date\":\"1\",\"show_title\":1,\"show_tag\":\"1\",\"show_des\":\"0\",\"show_cat\":0,\"format\":\"default\",\"col\":3,\"thumb_size\":\"359x203\",\"style\":\"style2\",\"offset\":\"\",\"num_words\":\"25\",\"post__in\":\"\",\"post__not_in\":[\"29422\",\" 30172\",\" 30192\"],\"not_video\":\"1\",\"filter\":\"1\",\"is_banner\":\"1\",\"posts_per_page\":\"9\",\"post_type\":\"post\",\"paged\":\"\",\"post_status\":\"publish\",\"post_password\":\"\"}'>\n                    <!-- <li data-filter=\"*\" class=\"active\"><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/\">All<\/a><\/li> -->\n                    <li data-filter=\"*\" class=\"active\"><a href=\"\">All<\/a><\/li>\n                        <li><a href=\"74\" data-id=\"74\">Podcast<\/a><\/li><li><a href=\"6\" data-id=\"6\">Video<\/a><\/li><li><a href=\"5\" data-id=\"5\">Articles<\/a><\/li><li><a href=\"1\" data-id=\"1\">News<\/a><\/li>                    <\/ul>\n                            <div class=\"post-grid grid-row default\" data-format=\"default\">\n                                <div class=\"grid-md-4 grid-lg-4 size-light margin post-31273 post type-post status-publish format-standard has-post-thumbnail hentry category-articles category-news tag-the-australian\" data-mb=\"35\" data-md=\"30\" >\n                        <article class=\"style2 default\">\n                            <a  href=\"https:\/\/www.theaustralian.com.au\/business\/stockhead\/content\/prescient-therapeutics-takes-cap-raise-to-98m-to-fasttrack-cancer-treatment\/news-story\/f8e118e0564588743f859d0e9fd12fab\" class=\"\">\n                            <div class=\"post-thumbnail rel\">\n                                <img loading=\"lazy\" decoding=\"async\" class=\"vc_single_image-img \" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-31-151050-359x203.png\" width=\"359\" height=\"203\" alt=\"Screenshot 2025-07-31 151050\" title=\"Screenshot 2025-07-31 151050\" \/>                                 <a class=\"tag\" href=https:\/\/template.reachmarkets.com.au\/investorportal\/tag\/the-australian\/>The Australian <\/a> \n                            <\/div>\n                            <\/a>\n                            <div class=\"post-content\">\n                                                                 <h3 class=\"post-title fw600\"><a class=\"\" href=\"https:\/\/www.theaustralian.com.au\/business\/stockhead\/content\/prescient-therapeutics-takes-cap-raise-to-98m-to-fasttrack-cancer-treatment\/news-story\/f8e118e0564588743f859d0e9fd12fab\">Prescient Therapeutics takes cap raise to $9.8m to fast-track cancer treatment<\/a><\/h3>\n                                                                 <div class=\"date style2\">July 31, 2025<\/div>                                                                \n\n                             \n                                                 \n                                <p><\/p>\n                                \n                                        \n                                                                \n                                                        \n                            <\/div>\n                        <\/article>\n                    <\/div>\n                    \n                                        <div class=\"grid-md-4 grid-lg-4 size-light margin post-31262 post type-post status-publish format-standard has-post-thumbnail hentry category-articles category-news tag-proactive-investors\" data-mb=\"35\" data-md=\"30\" >\n                        <article class=\"style2 default\">\n                            <a  href=\"https:\/\/www.proactiveinvestors.com.au\/companies\/news\/1075693\/prescient-advances-ptx-100-trial-after-fda-fast-track-nod-raises-6-8-million-for-development-1075693.html\" class=\"\">\n                            <div class=\"post-thumbnail rel\">\n                                <img loading=\"lazy\" decoding=\"async\" class=\"vc_single_image-img \" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-31-083319-359x203.png\" width=\"359\" height=\"203\" alt=\"Screenshot 2025-07-31 083319\" title=\"Screenshot 2025-07-31 083319\" \/>                                 <a class=\"tag\" href=https:\/\/template.reachmarkets.com.au\/investorportal\/tag\/proactive-investors\/>Proactive Investors <\/a> \n                            <\/div>\n                            <\/a>\n                            <div class=\"post-content\">\n                                                                 <h3 class=\"post-title fw600\"><a class=\"\" href=\"https:\/\/www.proactiveinvestors.com.au\/companies\/news\/1075693\/prescient-advances-ptx-100-trial-after-fda-fast-track-nod-raises-6-8-million-for-development-1075693.html\">Prescient advances PTX-100 trial after FDA Fast Track nod, raises $6.8 million for development<\/a><\/h3>\n                                                                 <div class=\"date style2\">July 30, 2025<\/div>                                                                \n\n                             \n                                                 \n                                <p><\/p>\n                                \n                                        \n                                                                \n                                                        \n                            <\/div>\n                        <\/article>\n                    <\/div>\n                    \n                                        <div class=\"grid-md-4 grid-lg-4 size-light margin post-31227 post type-post status-publish format-standard has-post-thumbnail hentry category-articles category-news tag-the-australian\" data-mb=\"35\" data-md=\"30\" >\n                        <article class=\"style2 default\">\n                            <a  href=\"https:\/\/www.theaustralian.com.au\/business\/stockhead\/content\/prescient-focuses-on-advancing-lead-cancer-drug-toward-pivotal-trial\/news-story\/a2b93255af2997fefbc50a592997407f\" class=\"\">\n                            <div class=\"post-thumbnail rel\">\n                                <img loading=\"lazy\" decoding=\"async\" class=\"vc_single_image-img \" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/The-Aus-PTX-359x203.png\" width=\"359\" height=\"203\" alt=\"The Aus-PTX\" title=\"The Aus-PTX\" \/>                                 <a class=\"tag\" href=https:\/\/template.reachmarkets.com.au\/investorportal\/tag\/the-australian\/>The Australian <\/a> \n                            <\/div>\n                            <\/a>\n                            <div class=\"post-content\">\n                                                                 <h3 class=\"post-title fw600\"><a class=\"\" href=\"https:\/\/www.theaustralian.com.au\/business\/stockhead\/content\/prescient-focuses-on-advancing-lead-cancer-drug-toward-pivotal-trial\/news-story\/a2b93255af2997fefbc50a592997407f\">Prescient focuses on advancing lead cancer drug toward pivotal trial<\/a><\/h3>\n                                                                 <div class=\"date style2\">July 28, 2025<\/div>                                                                \n\n                             \n                                                 \n                                <p><\/p>\n                                \n                                        \n                                                                \n                                                        \n                            <\/div>\n                        <\/article>\n                    <\/div>\n                    \n                                        <div class=\"grid-md-4 grid-lg-4 size-light margin post-31173 post type-post status-publish format-standard has-post-thumbnail hentry category-articles category-news tag-proactive-investors\" data-mb=\"35\" data-md=\"30\" >\n                        <article class=\"style2 default\">\n                            <a  href=\"https:\/\/www.proactiveinvestors.com.au\/companies\/news\/1075333\/prescient-therapeutics-eyes-inflection-point-us-1-8-billion-market-with-cancer-drug-ptx-100-1075333.html\" class=\"\">\n                            <div class=\"post-thumbnail rel\">\n                                <img loading=\"lazy\" decoding=\"async\" class=\"vc_single_image-img \" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-25-152422-359x203.png\" width=\"359\" height=\"203\" alt=\"Screenshot 2025-07-25 152422\" title=\"Screenshot 2025-07-25 152422\" \/>                                 <a class=\"tag\" href=https:\/\/template.reachmarkets.com.au\/investorportal\/tag\/proactive-investors\/>Proactive Investors <\/a> \n                            <\/div>\n                            <\/a>\n                            <div class=\"post-content\">\n                                                                 <h3 class=\"post-title fw600\"><a class=\"\" href=\"https:\/\/www.proactiveinvestors.com.au\/companies\/news\/1075333\/prescient-therapeutics-eyes-inflection-point-us-1-8-billion-market-with-cancer-drug-ptx-100-1075333.html\">Prescient Therapeutics eyes &#8216;inflection point&#8217;, US$1.8 billion market with cancer drug PTX-100<\/a><\/h3>\n                                                                 <div class=\"date style2\">July 24, 2025<\/div>                                                                \n\n                             \n                                                 \n                                <p><\/p>\n                                \n                                        \n                                                                \n                                                        \n                            <\/div>\n                        <\/article>\n                    <\/div>\n                    \n                                        <div class=\"grid-md-4 grid-lg-4 size-light margin post-31168 post type-post status-publish format-standard has-post-thumbnail hentry category-articles category-news tag-small-caps\" data-mb=\"35\" data-md=\"30\" >\n                        <article class=\"style2 default\">\n                            <a  href=\"https:\/\/smallcaps.com.au\/prescient-therapeutics-ptx-100-cutaneous-t-cell-lymphoma-therapy-commercialisation\/\" class=\"\">\n                            <div class=\"post-thumbnail rel\">\n                                <img loading=\"lazy\" decoding=\"async\" class=\"vc_single_image-img \" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-25-152011-359x203.png\" width=\"359\" height=\"203\" alt=\"Screenshot 2025-07-25 152011\" title=\"Screenshot 2025-07-25 152011\" \/>                                 <a class=\"tag\" href=https:\/\/template.reachmarkets.com.au\/investorportal\/tag\/small-caps\/>Small Caps <\/a> \n                            <\/div>\n                            <\/a>\n                            <div class=\"post-content\">\n                                                                 <h3 class=\"post-title fw600\"><a class=\"\" href=\"https:\/\/smallcaps.com.au\/prescient-therapeutics-ptx-100-cutaneous-t-cell-lymphoma-therapy-commercialisation\/\">Prescient Therapeutics Moves Advanced PTX-100 Cutaneous T-Cell Lymphoma Therapy Closer to Commercialisation<\/a><\/h3>\n                                                                 <div class=\"date style2\">July 24, 2025<\/div>                                                                \n\n                             \n                                                 \n                                <p><\/p>\n                                \n                                        \n                                                                \n                                                        \n                            <\/div>\n                        <\/article>\n                    <\/div>\n                    \n                                        <div class=\"grid-md-4 grid-lg-4 size-light margin post-31085 post type-post status-publish format-standard has-post-thumbnail hentry category-news category-video tag-prescient-therapeutics\" data-mb=\"35\" data-md=\"30\" >\n                        <article class=\"style2 default\">\n                            <a  href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell-3\/\" class=\"\">\n                            <div class=\"post-thumbnail rel\">\n                                <img loading=\"lazy\" decoding=\"async\" class=\"vc_single_image-img \" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/03\/PTX-QA-3-359x203.png\" width=\"359\" height=\"203\" alt=\"PTX - Q&amp;A (3)\" title=\"PTX - Q&amp;A (3)\" \/>                                 <a class=\"tag\" href=https:\/\/template.reachmarkets.com.au\/investorportal\/tag\/prescient-therapeutics\/>Prescient Therapeutics <\/a> \n                            <\/div>\n                            <\/a>\n                            <div class=\"post-content\">\n                                                                 <h3 class=\"post-title fw600\"><a class=\"\" href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing-with-james-mcdonnell-3\/\">Investor Briefing with James McDonnell<\/a><\/h3>\n                                                                 <div class=\"date style2\">July 22, 2025<\/div>                                                                \n\n                             \n                                                 \n                                <p><\/p>\n                                \n                                        \n                                                                \n                                                        \n                            <\/div>\n                        <\/article>\n                    <\/div>\n                                                    <section id=\"gmb05e434\" style=\"padding:0 15px\"  class=\"wp-block-gutentor-m4 section-gmb05e434 gutentor-module gutentor-advanced-columns has-color-bg has-custom-bg stay stay-new\">\n                                    <div class=\"grid-container \" style=\"background: #00CE9A;\n                                        box-shadow: 10px 10px 20px rgba(0, 0, 0, 0.25);\n                                        border-radius: 5px;\">\n                                        <div class=\"grid-row\" >\n                                        <div id=\"col-gmc4b901\" class=\"wp-block-gutentor-m4-col col-gmc4b901 gutentor-single-column  grid-lg-4 grid-md-12 grid-12\">\n                                            <div id=\"section-gmc4b901\" class=\"section-gmc4b901 gutentor-col-wrap\">\n                                        <figure class=\"wp-block-image size-full image-stay desktop\"><img decoding=\"async\" src=\"https:\/\/prescienttherapeutics-rebuild.investorportal.com.au\/wp-content\/uploads\/2022\/07\/Mail-2-1.svg\" alt=\"\" class=\"wp-image-22106\">\n                                        <\/figure>\n                                        <figure class=\"wp-block-image size-full image-stay mobile\"><img decoding=\"async\" src=\"https:\/\/prescienttherapeutics-rebuild.investorportal.com.au\/wp-content\/uploads\/2022\/07\/Mail-2-1.svg\" alt=\"\" class=\"wp-image-22106\">\n                                        <\/figure>\n                                        <\/div>\n                                    <\/div>\n                                        <div id=\"col-gm09a1de\" class=\"wp-block-gutentor-m4-col col-gm09a1de gutentor-single-column  grid-lg-8 grid-md-12 grid-12 right-stay \">\n                                            <div id=\"section-gm09a1de\" class=\"section-gm09a1de gutentor-col-wrap mbn\">\n                                        <p class=\"has-white-color has-text-color\" style=\"font-size:20px\">To stay up to date with Prescient Therapeutics or to receive alerts on company events, please register your details.<\/p>\n                                        <div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n                                        <div id=\"section-gb00d24\" class=\"button-sidebar wp-block-gutentor-e2 section-gb00d24 gutentor-element gutentor-element-button button-align-left-desktop button-sidebar ticss-e952a764 fw600\">\n                                            <span class=\"gutentor-button-wrap\"><a class=\"gutentor-button gutentor-block-button gutentor-icon-hide button-stay\" href=\"#\"><i class=\"gutentor-button-icon fas fa-book\"><\/i><span>Stay up to date<\/span><\/a><\/span>\n                                        <\/div>\n                                        <\/div>\n                                    <\/div>\n                                        <\/div>\n                                    <\/div>\n                                <\/section>\n                            \n                                        <div class=\"grid-md-4 grid-lg-4 size-light margin post-31073 post type-post status-publish format-standard has-post-thumbnail hentry category-articles category-news category-video tag-hot-copper\" data-mb=\"35\" data-md=\"30\" >\n                        <article class=\"style2 default\">\n                            <a  href=\"https:\/\/hotcopper.com.au\/news\/asx-news\/152339\/this-rare-type-of-lymphoma-ruins-the-body-so-do-existing-treatments-prescient-could-have-a-solution\/\" class=\"\">\n                            <div class=\"post-thumbnail rel\">\n                                <img loading=\"lazy\" decoding=\"async\" class=\"vc_single_image-img \" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/06\/PTX_Hot-Copper-26.06.25-359x203.png\" width=\"359\" height=\"203\" alt=\"PTX_Hot Copper 26.06.25\" title=\"PTX_Hot Copper 26.06.25\" \/>                                 <a class=\"tag\" href=https:\/\/template.reachmarkets.com.au\/investorportal\/tag\/hot-copper\/>Hot Copper <\/a> \n                            <\/div>\n                            <\/a>\n                            <div class=\"post-content\">\n                                                                 <h3 class=\"post-title fw600\"><a class=\"\" href=\"https:\/\/hotcopper.com.au\/news\/asx-news\/152339\/this-rare-type-of-lymphoma-ruins-the-body-so-do-existing-treatments-prescient-could-have-a-solution\/\">This rare type of lymphoma ruins the body \u2013 so do existing treatments. Prescient could have a solution<\/a><\/h3>\n                                                                 <div class=\"date style2\">July 21, 2025<\/div>                                                                \n\n                             \n                                                 \n                                <p><\/p>\n                                \n                                        \n                                                                \n                                                        \n                            <\/div>\n                        <\/article>\n                    <\/div>\n                    \n                                        <div class=\"grid-md-4 grid-lg-4 size-light margin post-31012 post type-post status-publish format-standard has-post-thumbnail hentry category-articles category-news tag-small-caps\" data-mb=\"35\" data-md=\"30\" >\n                        <article class=\"style2 default\">\n                            <a  href=\"https:\/\/smallcaps.com.au\/prescient-therapeutics-first-us-site-ptx-100-phase-2a-refractory-cutaneous-t-cell-lymphoma-trial\/\" class=\"\">\n                            <div class=\"post-thumbnail rel\">\n                                <img loading=\"lazy\" decoding=\"async\" class=\"vc_single_image-img \" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/featured-1752707563969-359x203.jpg\" width=\"359\" height=\"203\" alt=\"featured-1752707563969\" title=\"featured-1752707563969\" \/>                                 <a class=\"tag\" href=https:\/\/template.reachmarkets.com.au\/investorportal\/tag\/small-caps\/>Small Caps <\/a> \n                            <\/div>\n                            <\/a>\n                            <div class=\"post-content\">\n                                                                 <h3 class=\"post-title fw600\"><a class=\"\" href=\"https:\/\/smallcaps.com.au\/prescient-therapeutics-first-us-site-ptx-100-phase-2a-refractory-cutaneous-t-cell-lymphoma-trial\/\">Prescient Therapeutics Confirms First US Site for PTX-100 Phase 2a Refractory Cutaneous T-Cell Lymphoma Trial<\/a><\/h3>\n                                                                 <div class=\"date style2\">July 17, 2025<\/div>                                                                \n\n                             \n                                                 \n                                <p><\/p>\n                                \n                                        \n                                                                \n                                                        \n                            <\/div>\n                        <\/article>\n                    <\/div>\n                    \n                                        <div class=\"grid-md-4 grid-lg-4 size-light margin post-31023 post type-post status-publish format-standard has-post-thumbnail hentry category-articles category-news category-video tag-proactive-investors\" data-mb=\"35\" data-md=\"30\" >\n                        <article class=\"style2 default\">\n                            <a  href=\"https:\/\/www.proactiveinvestors.com\/companies\/news\/1074883\/prescient-therapeutics-ptx-100-trial-expands-to-top-us-cancer-centre.html\" class=\"\">\n                            <div class=\"post-thumbnail rel\">\n                                <img loading=\"lazy\" decoding=\"async\" class=\"vc_single_image-img \" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-17-123026-359x203.png\" width=\"359\" height=\"203\" alt=\"Screenshot 2025-07-17 123026\" title=\"Screenshot 2025-07-17 123026\" \/>                                 <a class=\"tag\" href=https:\/\/template.reachmarkets.com.au\/investorportal\/tag\/proactive-investors\/>Proactive Investors <\/a> \n                            <\/div>\n                            <\/a>\n                            <div class=\"post-content\">\n                                                                 <h3 class=\"post-title fw600\"><a class=\"\" href=\"https:\/\/www.proactiveinvestors.com\/companies\/news\/1074883\/prescient-therapeutics-ptx-100-trial-expands-to-top-us-cancer-centre.html\">Prescient Therapeutics&#8217; PTX-100 trial expands to top US cancer centre<\/a><\/h3>\n                                                                 <div class=\"date style2\">July 16, 2025<\/div>                                                                \n\n                             \n                                                 \n                                <p><\/p>\n                                \n                                        \n                                                                \n                                                        \n                            <\/div>\n                        <\/article>\n                    <\/div>\n                    \n                    <div class=\"anc\"><span aria-current=\"page\" class=\"page-numbers current\">1<\/span>\n<a class=\"page-numbers\" href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages\/34\/page\/2\/\">2<\/a>\n<a class=\"page-numbers\" href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages\/34\/page\/3\/\">3<\/a>\n<span class=\"page-numbers dots\">&hellip;<\/span>\n<a class=\"page-numbers\" href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages\/34\/page\/43\/\">43<\/a>\n<a class=\"next page-numbers\" href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages\/34\/page\/2\/\">\u276d<\/a><\/div>        <\/div>\n        \n\n\n<div class=\"form-sidebar\"><a class=\"closes\" style=\"cursor: pointer;\"><img decoding=\"async\" src=\"https:\/\/prescienttherapeutics-rebuild.investorportal.com.au\/wp-content\/uploads\/2022\/07\/close-btn.svg\"><\/a><\/div>\n\n\n<div class=\"form-sidebar\"><a class=\"closes\" style=\"cursor: pointer;\"><img decoding=\"async\" src=\"https:\/\/prescienttherapeutics-rebuild.investorportal.com.au\/wp-content\/uploads\/2022\/07\/close-btn.svg\"><\/a><div style=\"padding: 0 0 0 0; position: relative;\">\n<h2 class=\"the-latest-news\" style=\"color: #0089C4; text-align: left; font-size: 24px!important; margin-bottom: 5px;\">Receive email updates<\/h2>\n<p><!-- Hotjar Tracking Code for https:\/\/template.reachmarkets.com.au\/investorportal\/ --> <script> (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2736440,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https:\/\/static.hotjar.com\/c\/hotjar-','.js?sv='); <\/script> <!--[if lte IE 8]> <script charset=\"utf-8\" type=\"text\/javascript\" src=\"\/\/js.hsforms.net\/forms\/v2-legacy.js\"><\/script> <![endif]--> <script  charset=\"utf-8\" type=\"text\/javascript\" src=\"\/\/js.hsforms.net\/forms\/v2.js\"><\/script> <script> hbspt.forms.create({ region: \"na1\", portalId: \"7664250\", formId: \"8be09ab6-f2b3-484c-8108-42cd66e3980d\", formInstanceId: \"slide\", onFormSubmitted: function($form) { jQuery('.byclick').hide(); gtag_report_conversion('#'); jQuery('.the-latest-news').text('Receive email updates'); } }); <\/script><a id=\"hypelinkbkt\" class=\"hypelinkbkt\" style=\"font-weight: 700; font-size: 14px;\" target=\"blank\" rel=\"noopener noreferrer\">What is a 708 investor?<\/a><\/p>\n<p class=\"byclick\" style=\"font-size: 14px !important;margin-bottom: 0px;\">By submitting this form, I agree to the terms of the&nbsp;<a class=\"md-opjjpmhoiojifppkkcdabiobhakljdgm_doc\" href=\"https:\/\/reachmarkets.com.au\/financial-services-guide\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong style=\"font-size: 14px !important;\">Reach Markets Financial Services Guide<\/strong><\/a>&nbsp;that includes the&nbsp;<a class=\"md-opjjpmhoiojifppkkcdabiobhakljdgm_doc\" href=\"https:\/\/reachmarkets.com.au\/privacy-reach\/\" target=\"_blank\" rel=\"noopener noreferrer\"><strong style=\"font-size: 14px !important;\">Privacy Statement<\/strong><\/a>. Reach Markets has been engaged by Prescient Therapeutics Limited to assist with their investor communications and may receive fees for its services.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":37,"featured_media":29291,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-34","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>News &amp; media - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News &amp; media - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-20T03:02:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/03\/Frame-641-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/\",\"name\":\"News & media - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/03\/Frame-641-1.png\",\"datePublished\":\"2020-10-20T01:37:20+00:00\",\"dateModified\":\"2025-06-20T03:02:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/03\/Frame-641-1.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/03\/Frame-641-1.png\",\"width\":650,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; media\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"News & media - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"News & media - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/","og_site_name":"PTX Therapeutics","article_modified_time":"2025-06-20T03:02:38+00:00","og_image":[{"width":650,"height":360,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/03\/Frame-641-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/","name":"News & media - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/03\/Frame-641-1.png","datePublished":"2020-10-20T01:37:20+00:00","dateModified":"2025-06-20T03:02:38+00:00","breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/03\/Frame-641-1.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2023\/03\/Frame-641-1.png","width":650,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/news-media\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"News &#038; media"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages\/34","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/37"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=34"}],"version-history":[{"count":73,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages\/34\/revisions"}],"predecessor-version":[{"id":30695,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/pages\/34\/revisions\/30695"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/29291"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=34"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}